secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001104659-25-076825
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter
---------------------------------------------------------------------------

- Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.
- Total net product revenue $15.0M, up slightly from $14.9M year-over-year.
- Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.
- SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.
- Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/0001104659-25-076825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer